Axsome TherapeuticsAXSM
About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Employees: 589
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
61% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 38
49% more call options, than puts
Call options by funds: $181M | Put options by funds: $121M
38% more funds holding in top 10
Funds holding in top 10: 8 [Q3] → 11 (+3) [Q4]
5% more funds holding
Funds holding: 274 [Q3] → 288 (+14) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 90
1.48% less ownership
Funds ownership: 79.74% [Q3] → 78.26% (-1.48%) [Q4]
9% less capital invested
Capital invested by funds: $3.44B [Q3] → $3.14B (-$293M) [Q4]
Research analyst outlook
14 Wall Street Analysts provided 1 year price targets over the past 3 months
14 analyst ratings
Jefferies Andrew Tsai 17% 1-year accuracy 1 / 6 met price target | 94%upside $200 | Buy Initiated | 7 Apr 2025 |
HC Wainwright & Co. Raghuram Selvaraju 29% 1-year accuracy 96 / 335 met price target | 94%upside $200 | Buy Reiterated | 3 Apr 2025 |
Needham Ami Fadia 12% 1-year accuracy 20 / 164 met price target | 49%upside $153 | Buy Reiterated | 1 Apr 2025 |
Mizuho Graig Suvannavejh 26% 1-year accuracy 6 / 23 met price target | 110%upside $216 | Outperform Maintained | 27 Mar 2025 |
Baird Joel Beatty 18% 1-year accuracy 7 / 38 met price target | 55%upside $160 | Outperform Maintained | 3 Mar 2025 |
Financial journalist opinion
Based on 14 articles about AXSM published over the past 30 days









